Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Thousands |
2 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Dec. 31, 2020 |
Dec. 31, 2020 |
Dec. 31, 2019 |
Oct. 20, 2020 |
Jun. 30, 2020 |
|
| Goodwill | $ 746,666 | $ 746,666 | $ 728,308 | ||
| Cash paid, net of cash acquired | 9,765 | $ (0) | |||
| Changzhou Eminence Biotechnology [Member] | |||||
| Current assets, net of cash | 3,145 | 3,145 | |||
| Equipment and other long-term assets | 1,639 | 1,639 | |||
| Goodwill | 8,811 | 8,811 | |||
| Total assets acquired | 22,506 | 22,506 | |||
| Liabilities | 1,436 | 1,436 | |||
| Deferred income taxes, net | 2,320 | 2,320 | |||
| Net assets acquired | 18,750 | 18,750 | |||
| Cash paid, net of cash acquired | 9,765 | ||||
| Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value | 8,985 | 8,985 | $ 9,000 | ||
| Net assets acquired | 18,750 | ||||
| Changzhou Eminence Biotechnology [Member] | Developed Technology Rights [Member] | |||||
| Intangible assets | 6,778 | 6,778 | |||
| Changzhou Eminence Biotechnology [Member] | Customer Relationships [Member] | |||||
| Intangible assets | $ 2,133 | $ 2,133 | |||
| X | ||||||||||
- Definition Amount of assets acquired, including goodwill, at the acquisition date. No definition available.
|
| X | ||||||||||
- Definition Amount of equipment and other long-term assets acquired at the acquisition date. No definition available.
|
| X | ||||||||||
- Definition Amount of liabilities excluding deferred income taxes assumed at the acquisition date. No definition available.
|
| X | ||||||||||
- Definition This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|